Anticoagulant and Antiplatelet Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease

Table 3

ESC Anticoagulation regimen in patients with low-intermediate bleeding risk after stent implantation [1].

Setting stent	Anticoagulation (HAS-BLED 0–2)
Elective BMS	1 month: VKA + aspirin + clopidogrel; Lifelong: VKA
Elective DES	3* months: VKA + aspirin + clopidogrel; Up to 12th month: VKA + clopidogrel (or aspirin); Lifelong: VKA
ACS BMS/DES	6 months: VKA + aspirin+clopidogrel; Up to 12th month: VKA + clopidogrel (oraspirin); Lifelong: VKA

ACS: acute coronary syndrome, BMS: bare metal stent, DES: drug eluting stent, VKA: vitamin K-antagonist, *6 months in patients with a paclitaxel-eluting stent. The INR should be adjusted according to concomitant antiplatelet therapy (2-3 in vitamin K-antagonist monotherapy and 2–2.5 in case of concomitant antiplatelet therapy).